bexarotene gel 1% — CareFirst (Caremark)
primary cutaneous marginal zone lymphoma
Initial criteria
- Authorization may be granted for treatment of primary cutaneous marginal zone lymphoma or primary cutaneous follicle center lymphoma.
Reauthorization criteria
- Authorization may be granted if no evidence of unacceptable toxicity or disease progression while on current regimen.
Approval duration
12 months